The introduction of PCV-10, along with a “catch-up” campaign for 1-4 year olds, led to dramatic reductions in the rates of pneumococcal pneumonia in adults (≥18 years old) in a rural area of Kenya with high rates of both adult pneumococcal pneumonia and HIV. Over five years following the vaccine introduction, the incidence rates among adults were 47-94% lower each year than in the pre-vaccine period, with similar declines for HIV-infected and HIV-uninfected adults.
Full Citation:
Bigogo GM, Audi A, Auko J et al.. 2019. Indirect effects of 10-Valent pneumococcal conjugate vaccine against adult pneumococcal pneumonia in rural western Kenya. Clinical Infectious Diseases. 69(12).
Title of Article: Indirect effects of 10-Valent pneumococcal conjugate vaccine against adult pneumococcal pneumonia in rural western Kenya
Author(s): Bigogo GM, Audi A, Auko J et al.
Publication Year: 2019
Publication Name: Clinical Infectious Diseases
Publication Volume: 69(12)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pubmed/30785189
DOI (Digital Object Identifier): 10.1093/cid/ciz139
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Kenya
WHO Regions: Africa